|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wadhwa R, Song S, Lee JS, Yao Y, Wei Q and
Ajani JA: Gastric cancer-molecular and clinical dimensions. Nat Rev
Clin Oncol. 10:643–655. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McLean MH and El-Omar EM: Genetics of
gastric cancer. Nat Rev Gastroenterol Hepatol. 11:664–674. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dong D, Ruuska SE, Levinthal DJ and Noy N:
Distinct roles for cellular retinoic acid-binding proteins I and II
in regulating signaling by retinoic acid. J Biol Chem.
274:23695–23698. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kanda M, Shimizu D, Tanaka H, Shibata M,
Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, Fujii T, et
al: Metastatic pathway-specific transcriptome analysis identifies
MFSD4 as a putative tumor suppressor and biomarker for hepatic
metastasis in patients with gastric cancer. Oncotarget.
7:13667–13679. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu JY, Peng CW, Yang XJ, Huang CQ and Li
Y: The prognosis role of AJCC/UICC 8th edition staging
system in gastric cancer, a retrospective analysis. Am J Transl
Res. 10:292–303. 2018.
|
|
7
|
Kanda M, Murotani K, Kobayashi D, Tanaka
C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M
and Kodera Y: Postoperative adjuvant chemotherapy with S-1 alters
recurrence patterns and prognostic factors among patients with
stage II/III gastric cancer: A propensity score matching analysis.
Surgery. 158:1573–1580. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Foo M and Leong T: Adjuvant therapy for
gastric cancer: Current and future directions. World J
Gastroenterol. 20:13718–13727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kanda M, Nomoto S, Oya H, Takami H,
Shimizu D, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S,
et al: The expression of melanoma-associated antigen D2 both in
surgically resected and serum samples serves as clinically relevant
biomarker of gastric cancer progression. Ann Surg Oncol. 23(Suppl
2): S214–S221. 2016. View Article : Google Scholar
|
|
10
|
Umeda S, Kanda M, Miwa T, Tanaka H, Tanaka
C, Kobayashi D, Suenaga M, Hattori N, Hayashi M, Yamada S, et al:
Expression of sushi domain containing two reflects the malignant
potential of gastric cancer. Cancer Med. 7:5194–5204. 2018.
View Article : Google Scholar :
|
|
11
|
Kanda M, Shimizu D, Fujii T, Sueoka S,
Tanaka Y, Ezaka K, Takami H, Tanaka H, Hashimoto R, Iwata N, et al:
Function and diagnostic value of Anosmin-1 in gastric cancer
progression. Int J Cancer. 138:721–730. 2016. View Article : Google Scholar
|
|
12
|
Kanda M, Shimizu D, Tanaka H, Tanaka C,
Kobayashi D, Hayashi M, Iwata N, Niwa Y, Yamada S, Fujii T, et al:
Significance of SYT8 for the detection, prediction, and treatment
of peritoneal metastasis from gastric cancer. Ann Surg.
267:495–503. 2018. View Article : Google Scholar
|
|
13
|
Shimizu D, Kanda M, Tanaka H, Kobayashi D,
Tanaka C, Hayashi M, Iwata N, Niwa Y, Takami H, Yamada S, et al:
GPR155 serves as a predictive biomarker for hematogenous metastasis
in patients with gastric cancer. Sci Rep. 7:420892017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shimizu D, Kanda M, Sugimoto H, Shibata M,
Tanaka H, Takami H, Iwata N, Hayashi M, Tanaka C, Kobayashi D, et
al: The protein arginine methyltransferase 5 promotes malignant
phenotype of hepatocellular carcinoma cells and is associated with
adverse patient outcomes after curative hepatectomy. Int J Oncol.
50:381–386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kilkenny C, Browne WJ, Cuthill IC, Emerson
M and Altman DG: Improving bioscience research reporting: The
ARRIVE guidelines for reporting animal research. PLOS Biol.
8:e10004122010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Szász AM, Lánczky A, Nagy Á, Förster S,
Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B:
Cross-validation of survival associated biomarkers in gastric
cancer using transcriptomic data of 1,065 patients. Oncotarget.
7:49322–49333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Persaud SD, Park SW, Ishigami-Yuasa M,
Koyano-Nakagawa N, Kagechika H and Wei LN: All trans-retinoic acid
analogs promote cancer cell apoptosis through non-genomic Crabp1
mediating ERK1/2 phosphorylation. Sci Rep. 6:223962016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Persaud SD: The functional role of
retinoic acid and the cellular retinoic acid binding protein 1
(Crabp1) in tumor suppression. 141:2018.
|
|
19
|
Tanaka K, Imoto I, Inoue J, Kozaki K,
Tsuda H, Shimada Y, Aiko S, Yoshizumi Y, Iwai T, Kawano T and
Inazawa J: Frequent methylation-associated silencing of a candidate
tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma.
Oncogene. 26:6456–6468. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Celestino R, Nome T, Pestana A, Hoff AM,
Gonçalves AP, Pereira L, Cavadas B, Eloy C, Bjøro T,
Sobrinho-Simões M, et al: CRABP1, C1QL1 and LCN2 are biomarkers of
differentiated thyroid carcinoma, and predict extrathyroidal
extension. BMC Cancer. 18:682018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang Y, de la Chapelle A and Pellegata
NS: Hypermethylation, but not LOH, is associated with the low
expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J
Cancer. 104:735–744. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kainov Y, Favorskaya I, Delektorskaya V,
Chemeris G, Komelkov A, Zhuravskaya A, Trukhanova L, Zueva E,
Tavitian B, Dyakova N, et al: CRABP1 provides high malignancy of
transformed mesenchymal cells and contributes to the pathogenesis
of mesenchymal and neuroendocrine tumors. Cell Cycle. 13:1530–1539.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu RZ, Garcia E, Glubrecht DD, Poon HY,
Mackey JR and Godbout R: CRABP1 is associated with a poor prognosis
in breast cancer: Adding to the complexity of breast cancer cell
response to retinoic acid. Mol Cancer. 14:1292015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar
|
|
26
|
Aiello NM and Kang Y: Context-dependent
EMT programs in cancer metastasis. J Exp Med. 216:1016–1026. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qu Y, Dang S and Hou P: Gene methylation
in gastric cancer. Clin Chim Acta Int J Clin Chem. 424:53–65. 2013.
View Article : Google Scholar
|
|
28
|
Takada H, Wakabayashi N, Dohi O, Yasui K,
Sakakura C, Mitsufuji S, Taniwaki M and Yoshikawa T: Tissue factor
pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant
promoter hypermethylation in gastric cancer. Cancer Genet
Cytogenet. 197:16–24. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kanda M and Kodera Y: Molecular mechanisms
of peritoneal dissemination in gastric cancer Molecular mechanisms
of peritoneal dissemination in gastric cancer. World J
Gastroenterol. 22:6829–6840. 2016. View Article : Google Scholar : PubMed/NCBI
|
